Communiqués Biocon Limited

Actions

BIOCON

INE376G01013

Recherche biotechnologique et médicale

Marché Fermé - NSE India S.E. 13:05:07 08/10/2026			Varia. 5j.	Varia. 1 janv.
350,00 ^INR	-2,78%		-5,48%	-11,14%

07/10	Les menaces existentielles s’ajoutent aux craintes de bulle alors que le sentiment à l’égard de l’intelligence artificielle (IA) se fait plus prudent lors des forums de Singapour	RE
09/09	Les actions indiennes s'orientent vers une ouverture atone face à la poussée du pétrole et aux tensions au Moyen-Orient	RE

Communiqués

02/09	Biocon Announces Supplemental U.S. FDA Approval For Prefilled Autoinjector For YESINTEK	AQ
24/08	Biocon Launches Aflibercept Biosimilar In The United States	AQ
10/07	Biocon Announces Publication of Pivotal Clinical Data Supporting Effectiveness of Yesafili, a Biosimilar to Eylea	AQ
30/03	Shreehas Tambe Appointed CEO and Managing Director of Biocon Limited, Effective April 1, 2026	AQ
28/01	S&P Global Upgrades Biocon Biologics Credit Rating to BB+ Revises Outlook to Stable	AQ
15/01	Biocon Limited Concludes Rs 4,150 Crore Equity Fundraise through a Oualified Institutions Placement	AQ
06/01	Biocon Biologics to Expand Biosimilar Oncology Portfolio, Outline Strategic Vision at the 2026 J.P. Morgan Healthcare Conference	GL
15/12	Biocon Biologics Signs Settlement and License Agreement to Commercialize Biosimilar Aflibercept Worldwide	AQ
23/10/25	Biocon Biologics Receives Health Canada Approval for Yesintek™ and Yesintek™ I.V. (ustekinumab), a Biosimilar to Stelara®	AQ
18/09/25	Biocon Biologics' Yesafili® (aflibercept) Now Publicly Funded in Ontario, Canada for the Advanced Treatment of Patients with Retinal Diseases	AQ
15/07/25	Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™, the First and Only Interchangeable Rapid-Acting Insulin Aspart in the United States	GL
27/06/25	Biocon Biologics Receives Health Canada Approval for Yesafili™ (aflibercept); First Global Launch Scheduled for July 2025	GL
05/05/25	Biocon Biologics Secures Strong Market Access Coverage for Yesintek in the United States Covering 100+ Million Lives	AQ
10/03/25	Biocon Biologics Announces Positive Results from Phase 3 Study of Yesintek Biosimilar to Ustekinumab for Chronic Plaque Psoriasis	AQ
12/02/25	Biocon Foundation Dedicates Metro Pillars Public Art Project to Everyday Champions of Bengaluru	AQ
27/01/25	Biocon s S&P Global ESG Score Improves to 69 for 2024	AQ
10/01/25	Biocon Biologics to Present at the 43rd Annual J.P. Morgan Healthcare Conference	AQ
08/01/25	Biocon Biologics Completes One Year as an Integrated Global Biosimilars Enterprise	AQ
16/12/24	Biocon Group - Kiran Mazumdar-Shaw Honored by ISQ with Jamsetji Tata Award for Pioneering Biosciences Movement in India	AQ
12/12/24	Biocon Biologics Recognized as Asia IP Elite for 2024 by IAM, Cementing Leadership in Intellectual Property Excellence	AQ
02/12/24	Biocon Celebrates 46th Founder's Day with Anthem Launch, Walkathon, Leadership Talk and Experience Center Inauguration	AQ
28/11/24	Biocon Biologics Supports Diabetes Africa to Drive Progress in Embedding Specialist Nurses in Diabetes Care in Ethiopia	AQ
29/10/24	Biocon Continues to be Among Science Magazine's Top 10 Global Employers List	AQ
28/10/24	Biocon Foundation Honored with Doing Good for Bharat Awards 2024 in Healthcare Category for eLAJ Smart Clinics by the CSR Box	AQ
24/10/24	Biocon Biologics Announces Results of Aflibercept Switching Study at American Academy of Ophthalmology Annual Meeting	AQ